版本:
中国

BRIEF-Cleveland Biolabs announces commencement of in Vivo Biocomparability study

April 17 Cleveland Biolabs Inc

* Cleveland Biolabs announces commencement of in Vivo biocomparability study

* FDA provided CBLI with its consent for initiation of an in Vivo Biocomparability study of the formulations in non-human primates

* Planned biocomparability study is funded in part by department of defense joint Warfighter Medical Research Program contract

* FDA completed its review of a side-by-side analytical comparison of two formulations of entolimod Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐